ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Oncology"

  • Abstract Number: 0202 • ACR Convergence 2024

    Survival in Patients with Rheumatoid Arthritis and Early-Stage Colorectal, Lung, or Prostate Cancer Receiving Tumor Necrosis Factor Alpha Inhibitors

    Maria Suarez-Almazor1, Juan Ruiz2, Xiudong Lei1, Hui Zhao1, Suja Rajan3, Heather Lin1 and Sharon Giordano1, 1MD Anderson Cancer Center, Houston, TX, 2MD Anderson, Houston, TX, 3The University of Texas Health Science Center at Houston, Houston, TX

    Background/Purpose: There is concern about the use of tumor necrosis factor inhibitors (TNFi) in patients with early cancer given their immunosuppressant effects. Few studies have…
  • Abstract Number: 1986 • ACR Convergence 2024

    Disease Flare Following Immune Checkpoint Inhibition in Patients with Cancer and Preexisting Vasculitis

    Juan Sevillano1, Yixuan Zhou2, Juan Ruiz3, Noha Abdel-Wahab4 and Maria Suarez-Almazor1, 1MD Anderson Cancer Center, Houston, TX, 2Baylor College of Medicine, Houston, 3MD Anderson, Houston, TX, 4University of Texas MD Anderson Cancer Center, houston, TX

    Background/Purpose: Immune checkpoint inhibitors (ICI) are effective therapies for patients with cancer, but they often cause immune-related adverse events (irAE). There is limited data on…
  • Abstract Number: 0474 • ACR Convergence 2024

    Association Between Rheumatoid Arthritis and Survival After Cancer: A Systematic Literature Review and Meta-analysis

    Joshua Hsieh1, Avneet Kaur2, Hemant Khandelia3, Teresa Jewell4, Aman Singh5, Lauren Barkley6, Ishan Bansal7, Simmi Oberoi8 and Namrata Singh9, 1Lakeside High School, Seattle, WA, 2SUNY Upstate, Buffalo, NY, 3AIIMS, New Delhi, Delhi, India, 4University of Washington, Seattle, WA, 5Rajindra Hospital, Patiala, Punjab, India, 6Brandeis University, Boston, MA, 7Yale University, New Haven, CT, 8Rajindra Hospital, New Delhi, India, 9University of Washington, Bellevue, WA

    Background/Purpose: Increasing evidence suggests that inflammation, a hallmark of rheumatoid arthritis (RA), is associated with an elevated risk of cancer and can influence cancer outcomes.…
  • Abstract Number: 2004 • ACR Convergence 2024

    Rheumatic Complications Post-CAR-T Cell Therapy. Experience of a Single Center

    Jose Alfredo Gomez-Puerta1, Ana Monegal1, Andrés Ponce2, Pilar Peris3, Nuria Martínez4, Valentin Ortiz-Maldonado4, Ana Triguero4, Carlos Fernández de larrea4, Julio Delgado4, Raimon Sanmartí Sala1 and Manuel Juan5, 1Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain, 2Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, 3Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, 4Haematology Department, Hospital Clinic of Barcelona, Barcelona, Spain, 5Immunology Department, Hospital Clinic of Barcelona, Barcelona, Spain

    Background/Purpose: CAR-T cell therapy is a promising treatment for a range of systemic autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis, and antisynthetase syndrome,…
  • Abstract Number: 0486 • ACR Convergence 2024

    Associations Between Frailty and Incident Cancer and Cancer-related Mortality in Veterans with Rheumatoid Arthritis

    Bhavik Bansal1, Aaron Baraff2, Katherine Wysham3, James Andrews4, Bryant England5, Ted Mikuls5, Joshua Baker6, Kaleb Michaud5, Alexa Meara7, Una Makris8, Carolyn Presley9, ariela orkaby10 and Namrata Singh11, 1All India Institute of Medical Sciences, New Delhi, Delhi, India, 2VA PUGET SOUND SEATTLE, Seattle, WA, 3VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 4University of Alabama at Birmingham, Birmingham, AL, 5University of Nebraska Medical Center, Omaha, NE, 6University of Pennsylvania, Philadelphia, PA, 7The Ohio State University Wexner Medical Center, COLUMBUS, OH, 8UT Southwestern Medical Center and Dallas VA, Dallas, TX, 9The Ohio State Medical Center, Columbus, OH, 10New England VA Geriatric Research Education and Clinical Center/Boston VA/Division of Aging, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 11University of Washington, Bellevue, WA

    Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of cancer compared to the general population. Aging is one of the most important risk…
  • Abstract Number: 2117 • ACR Convergence 2024

    The Risk of Medication-related Osteonecrosis of the Jaw (MRONJ) in a Patient with Osteoporosis Treated with Antiresorptive Therapy and Undergoing Dental Care Is Negligible with a CTX Threshold Above 260

    Camille Ghio, Robinson Gravier-Dumonceau, Pierre Lafforgue, Roch Giorgi and Thao Pham, Assistance Publique-Hôpitaux de Marseille, Marseille, France

    Background/Purpose: Although antiresorptive treatments, including bisphosphonates and denosumab, have demonstrated their efficacy in treating osteoporosis. However, osteonecrosis of the jaw has been reported as a…
  • Abstract Number: 0916 • ACR Convergence 2024

    Isocitrate Dehydrogenase 2 Mutations Are Associated with Autoimmune Rheumatologic Diseases in Chronic Myelomonocytic Leukemia

    Mahmut Kaymakci1, Anuya Natu2, Clifford Csizmar2, Terra Lasho2, Christy Finke2, Abhishek Mangaonkar1, Aref Al-Kali1, Hassan Alkhateeb1, Jenna Fernandez2, Matthew Koster1, Cornelia Weyand2, Mrinal Patnaik1 and Kenneth Warrington1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester

    Background/Purpose: Somatic mutations occurring in the hematopoietic system can be associated with concomitant hematologic and inflammatory diseases. Chronic myelomonocytic leukemia (CMML) is a hematologic neoplasm…
  • Abstract Number: 2287 • ACR Convergence 2024

    Hydroxychloroquine and the Risk of Lymphoma Progression in Sjogren’s Disease: A Retrospective Case Control Study

    Christine Xue1, Monica Guma2 and Katherine Nguyen2, 1UC San Diego, San Diego, CA, 2UC San Diego, San Diego

    Background/Purpose:  Sjogren's disease is an autoimmune disorder characterized by chronic lymphocytic inflammation of the salivary and lacrimal glands. Affected individuals are at heightened risk of…
  • Abstract Number: 0989 • ACR Convergence 2024

    Malignancy Risk Between JAK Inhibitors and Anti-TNF Therapy Across Disease Indications: A Bayesian Network Meta-analysis

    Mark Gibson1, Benjamin Zuckerman2, Maryam Adas1, Mark Russell3, Katie Bechman1 and James Galloway4, 1King's College London, London, United Kingdom, 2King's College London, London, England, United Kingdom, 3King's College London, London, United Kingdom, 4Centre for Rheumatic Diseases, King's College London, London, United Kingdom

    Background/Purpose: To estimate the relative risk of malignancy between Janus kinase inhibitors (JAKi), tumour necrosis factor-α inhibitors (TNFi) and placebo in individuals with immune-mediated inflammatory…
  • Abstract Number: 1155 • ACR Convergence 2024

    Stratification of Cancer Risk in Idiopathic Inflammatory Myopathies. Application of the IMACS Guidelines to Enhance Screening

    Miriam Retuerto Guerrero1, Clara Moriano2, cristiana sieiro santos3 and elvira Diez álvarez4, 1Complejo Asistencial Universitario de León, Leon, Spain, 2Hospital León, LEON, Spain, 3Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, 4Complejo Asistencial Universitario de Leon, Leon

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) carry an elevated risk of cancer incidence. Recently published International Guidelines for IIM-associated cancer screening from the Myositis Assessment and…
  • Abstract Number: 1158 • ACR Convergence 2024

    Microvascular Differences Between Cancer and Non-cancer Anti-transcriptional Intermediary Factor 1 Gamma Antibody (anti-TIF1-γ) Associated Dermatomyositis Patients

    Sehreen Mumtaz1, Megan Sullivan2, Maximiliano Diaz Menindez3, Emily Craver4 and Florentina Berianu5, 1Mayo Clinic, Florida, Jacksonville, FL, 2Mayo Clinic Arizona, Scottsdale, AZ, 3Mayo Clinic School of Graduate Medical Education, Phoenix, AZ, 4Mayo Clinic Florida, Jacksonville, FL, 5mayo clinic, Ponte Vedra Beach, FL

    Background/Purpose: Nailfold videocapillaroscopy (NVC) findings have been studied to differ in different subsets of myositis-specific autoantibodies (MSAs) associated inflammatory myopathies. Prior investigations observed a statistically…
  • Abstract Number: 1327 • ACR Convergence 2024

    Association of Rheumatoid Arthritis and Frailty Status with Mortality in Patients with Renal Cell Carcinoma

    Sherwin Novin1, Sarah Holt2, Maya Swaminathan3, Jonathan Wright2, John Gore2, Kimme Hyrich4, Sizheng Zhao5, Jeffrey Sparks6, Una Makris7, Maria Suarez-Almazor8, Petros Grivas2, Sarah Psutka2 and Namrata Singh9, 1University of Washington, Seattle, WA, 2University of Washington, Seattle, 3MultiCare, Newcastle, WA, 4Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, 5Centre for Musculoskeletal Research, The University of Manchester, Liverpool, United Kingdom, 6Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, 7UT Southwestern Medical Center and Dallas VA, Dallas, TX, 8MD Anderson Cancer Center, Houston, TX, 9University of Washington, Bellevue, WA

    Background/Purpose: Few studies have evaluated clinical outcomes and prognosis of patients with cancer with and without rheumatoid arthritis (RA). Renal cell carcinoma (RCC) is particularly…
  • Abstract Number: 1353 • ACR Convergence 2024

    Association Between Frailty and Incident Cancer in Newly Diagnosed Rheumatoid Arthritis

    Bhavik Bansal1, Laura Gold2, Katherine Wysham3, James Andrews4, Alexa Meara5, Carolyn Presley6, Elad Sharon7, Jiha Lee8, Jennifer Barton9, Una Makris10 and Namrata Singh11, 1All India Institute of Medical Sciences, New Delhi, Delhi, India, 2University of Washington, Seattle, 3VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 4University of Alabama at Birmingham, Birmingham, AL, 5The Ohio State University Wexner Medical Center, COLUMBUS, OH, 6The Ohio State Medical Center, Columbus, OH, 7Dana Farber Cancer Institute, Boston, MA, 8University of Michigan, Ann Arbor, MI, 9VA Portland Health Care System/OHSU, Portland, OR, 10UT Southwestern Medical Center and Dallas VA, Dallas, TX, 11University of Washington, Bellevue, WA

    Background/Purpose: Rheumatoid Arthritis (RA) is associated with an increased risk of cancer, but the underlying risk factors remain poorly understood. Frailty is linked to an…
  • Abstract Number: 1374 • ACR Convergence 2024

    Exploring Two Decades of Therapeutic Challenges: A Monocentric Experience in Rheumatoid Arthritis Patients Battling Cancer

    Roba Ghossan1, Elodie Portier2, OLIVIER FOGEL3, Sophie Hecquet1, Astrid Dauchez1, Omar AL TABAA4, Marion THOMAS5, Julia Herrou1, Yannick Allanore6 and Jérôme Avouac7, 1COCHIN HOSPITAL, PARIS, France, 2Cochin Hospital, Bry sur Marne, France, 3AP-HP, Paris, France, 4APHP - Cochin Hospital, Paris, France, 5APHP, Paris, France, 6Université Paris Cité, Paris, France, 7Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France

    Background/Purpose: Managing inflammatory arthritis patients on biologics with a history of cancer remains a complex task in daily rheumatology practice and requires a thoughtful, individualized…
  • Abstract Number: 1400 • ACR Convergence 2024

    Disease Modifying Anti-rheumatic Drug Use and Association with Survival in Patients with Rheumatoid Arthritis and Newly Diagnosed Lung Cancer

    Varun Nandakumar1, Aaron Baraff2, Alexander Peterson2, Nicholas Smith3, Jennifer Barton4, Ann O'Hare2, Christopher Li5, Noel Weiss3 and Namrata Singh6, 1AIIMS, New Delhi, Delhi, India, 2VA PUGET SOUND SEATTLE, Seattle, WA, 3University of Washington, Seattle, WA, 4VA Portland Health Care System/OHSU, Portland, OR, 5University of Washington, Seattle, 6University of Washington, Bellevue, WA

    Background/Purpose: Despite the significant therapeutic benefits of various disease modifying anti-rheumatic drugs (DMARDs) in RA, concerns remain regarding their safety, particularly their potential impact on…
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology